APA (7th ed.) Citation

F, S., S, B., M, C., TI, G., CB, L., I, Á., . . . K, H. (2026). Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study. Journal of the American Academy of Dermatology, 94(6), 1705. https://doi.org/10.1016/j.jaad.2026.02.025

Chicago Style (17th ed.) Citation

F, Siebenhaar, et al. "Avapritinib Improves Cutaneous Involvement in Patients with Indolent Systemic Mastocytosis: Results from the Randomized, Phase 2, Interventional PIONEER Study." Journal of the American Academy of Dermatology 94, no. 6 (2026): 1705. https://doi.org/10.1016/j.jaad.2026.02.025.

MLA (9th ed.) Citation

F, Siebenhaar, et al. "Avapritinib Improves Cutaneous Involvement in Patients with Indolent Systemic Mastocytosis: Results from the Randomized, Phase 2, Interventional PIONEER Study." Journal of the American Academy of Dermatology, vol. 94, no. 6, 2026, p. 1705, https://doi.org/10.1016/j.jaad.2026.02.025.